06/15/18 10:37 AM H.R. 2851
On agreeing to the Maloney, Sean amendment; Agreed to by voice vote.
06/15/18 10:32 AM H.R. 2851
DEBATE - Pursuant to the provisions of H. Res. 934, the Committee of the Whole proceeded with 10 minutes of debate on the Sean Maloney amendment No. 3.
06/15/18 10:31 AM H.R. 2851
An amendment, offered by Mr. Maloney, Sean, numbered 3 printed in Part A of House Report 115-751 to require the Drug Enforcement Administration to make available a report on controlled substance analogues sold by means of the internet.
06/15/18 10:31 AM H.R. 2851
Amendment offered by Mr. Maloney, Sean.
06/15/18 10:31 AM H.R. 2851
On agreeing to the Jackson Lee amendment; Agreed to by voice vote.
06/15/18 10:24 AM H.R. 2851
DEBATE - Pursuant to the provisions of H. Res. 934, the Committee of the Whole proceeded with 10 minutes of debate on the Jackson Lee amendment No. 2.
06/15/18 10:24 AM H.R. 2851
An amendment, offered by Ms. Jackson Lee, numbered 2 printed in Part A of House Report 115-751 to strike the sentencing commission provision.
06/15/18 10:24 AM H.R. 2851
On agreeing to the Griffith amendment; Agreed to by voice vote.
06/15/18 10:15 AM H.R. 2851
DEBATE - Pursuant to the provisions of H. Res. 934, the Committee of the Whole proceeded with 10 minutes of debate on the Griffith amendment No. 1.
06/15/18 10:15 AM H.R. 2851
An amendment, offered by Mr. Griffith, numbered 1 printed in Part A of House Report 115-751 to incorporate an inter-agency agreement transmitted to Congress by the Office of National Drug Control Policy (ONDCP), the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Justice (DOJ). Specifically, the amendment clarifies when the Attorney General can temporarily and permanently schedule a drug or substance to the newly created schedule A and prevents the Attorney General from permanently scheduling that drug or substance if the Secretary of HHS determines that there is not sufficient potential for abuse. The amendment also clarifies under what circumstances an applicant for a schedule A registration may continue to conduct research with such schedule A substance while their application is pending, among their research accommodations.
